770 related articles for article (PubMed ID: 29214694)
21. Therapeutic approaches for the management of higher risk myelodysplastic syndromes.
Wang C; Sallman DA
Leuk Lymphoma; 2023 Mar; 64(3):511-524. PubMed ID: 36433645
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
Stone R; Sekeres M; Garcia-Manero G; Lyons RM
Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-15. PubMed ID: 19385003
[TBL] [Abstract][Full Text] [Related]
23. The search for better prognostic models in myelodysplastic syndromes.
Santos FP; Kantarjian H; Garcia-Manero G; Ravandi F
Curr Hematol Malig Rep; 2011 Mar; 6(1):13-21. PubMed ID: 21136214
[TBL] [Abstract][Full Text] [Related]
24. How we manage adults with myelodysplastic syndrome.
Fenaux P; Platzbecker U; Ades L
Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic strategies in low and high-risk MDS: What does the future have to offer?
Scalzulli E; Pepe S; Colafigli G; Breccia M
Blood Rev; 2021 Jan; 45():100689. PubMed ID: 32253020
[TBL] [Abstract][Full Text] [Related]
26. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Garcia-Manero G; Fenaux P
J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors and scoring systems in myelodysplastic syndromes.
Sanz GF; Sanz MA; Greenberg PL
Haematologica; 1998 Apr; 83(4):358-68. PubMed ID: 9592987
[TBL] [Abstract][Full Text] [Related]
28. The lower risk MDS patient at risk of rapid progression.
Mittelman M; Oster HS; Hoffman M; Neumann D
Leuk Res; 2010 Dec; 34(12):1551-5. PubMed ID: 20573398
[TBL] [Abstract][Full Text] [Related]
29. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
[TBL] [Abstract][Full Text] [Related]
30. Evolving treatment options of myelodysplastic syndromes.
Verbeek W; Ganser A
Ann Hematol; 2001 Sep; 80(9):499-509. PubMed ID: 11669297
[TBL] [Abstract][Full Text] [Related]
31. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.
Feld J; Belasen A; Navada SC
Expert Rev Anticancer Ther; 2020 Jun; 20(6):465-482. PubMed ID: 32479130
[TBL] [Abstract][Full Text] [Related]
32. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
33. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
34. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
35. Myelodysplastic syndromes: diagnosis and staging.
Malcovati L; Nimer SD
Cancer Control; 2008 Oct; 15 Suppl():4-13. PubMed ID: 18813205
[TBL] [Abstract][Full Text] [Related]
36. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellström-Lindberg E; Cermák J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Mądry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luño E; Bowen D; de Witte T
Br J Haematol; 2015 Aug; 170(3):372-83. PubMed ID: 25907546
[TBL] [Abstract][Full Text] [Related]
37. A comparative review of classification systems in myelodysplastic syndromes (MDS).
Bennett JM
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
[TBL] [Abstract][Full Text] [Related]
38. Refractory anemia and the myelodysplastic syndromes.
Lawrence LW
Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893
[TBL] [Abstract][Full Text] [Related]
39. Myelodysplastic syndrome: An update on diagnosis and therapy.
Koppel A; Schiller G
Curr Hematol Malig Rep; 2009 Jan; 4(1):10-6. PubMed ID: 20425433
[TBL] [Abstract][Full Text] [Related]
40. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]